Niowave was originally esablished with the objective of commercializing superconducting electron linear accelerators in a diversity of applications from healthcare to national security. Very active in the SBIR-STTR arena since soon after its founding, the firm has matured to become a lead player in superconducting accelerator research. In 2008, the firm had qualified as the second US vendor for accelerating cavities for the International Linear Collider and, in 2009, the first private company to design, fabricate, and test a superconducting electron injector. Now the firm is a domestic supplier of medical and industrial radioisotopes from uranium fission and stable targets. Isotope inventories available for purchase include alpha, beta, and gamma sources. The Niowave system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU). The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility.
